Apr 30 |
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
|
Apr 1 |
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript
|
Mar 27 |
DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript
|
Mar 27 |
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
|
Mar 27 |
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 27 |
Earnings Scheduled For March 27, 2024
|
Mar 26 |
DURECT Q4 2023 Earnings Preview
|
Mar 20 |
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
|
Mar 4 |
DURECT and Charles River enter agreement for alzet in U.S., Canada
|
Mar 4 |
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
|